1. Introduction {#sec1-jof-05-00112}
===============

In recent decades the incidence of mucormycosis has been increasing due to the growth of the number of severely immunocompromised patients. In developed countries, mucormycosis is mostly seen in hematological patients \[[@B1-jof-05-00112],[@B2-jof-05-00112]\]. Mucormycetes are the second most common causative agents of mycoses in hematological patients after the *Aspergillus* spp. and the third most common infection after candidiasis and aspergillosis in recipients of allogeneic hematopoietic stem cell transplants (allo-HSCT) \[[@B3-jof-05-00112],[@B4-jof-05-00112]\]. At the same time, increased frequency of mucormycosis in hematological patients was noted. For example, in France from 1997 to 2006 in this cohort of patients was recorded an increasing incidence of this fungal infection for more than 24% per year, among allo-HSCT recipients---for more than 15% per year \[[@B5-jof-05-00112]\]. Mucormycosis in hematological patients differs from other groups of patients (with diabetes mellitus, trauma, etc.) in etiology, localization of infection and high mortality rate, which exceeds 50%. An increasing incidence of mucormycosis in hematological patients can be associated with the intensification of cytostatic chemotherapy and with the use of inactive against mucormycetes voriconazole for prevention and treatment of aspergillosis \[[@B6-jof-05-00112],[@B7-jof-05-00112],[@B8-jof-05-00112]\]. According to our previous studies \[[@B9-jof-05-00112]\], mucormycosis was diagnosed in 52% of patients within 1--225 days after the development of invasive aspergillosis. Meanwhile voriconazole was used in 74% of these patients for the treatment of aspergillosis.

According to this the role of early diagnosis of mucormycosis is growing, but the disease is often detected late, often postmortem \[[@B6-jof-05-00112],[@B9-jof-05-00112],[@B10-jof-05-00112]\]. The clinical and radiological signs are similar to other mold mycoses, for example aspergillosis \[[@B11-jof-05-00112]\]. Standard diagnostic tests, such as microscopy and culture, have low sensitivity. There are no standardized serological methods for the diagnosis of mucormycosis \[[@B6-jof-05-00112],[@B7-jof-05-00112],[@B8-jof-05-00112],[@B11-jof-05-00112]\]. Histological examination is the "gold standard" of diagnosis but it is difficult to perform in this cohort of patients due to thrombocytopenia and severity of their condition. The use of new highly sensitive methods may be useful for the early diagnosis of mucormycosis in hematological patients \[[@B2-jof-05-00112],[@B11-jof-05-00112]\].

Molecular methods are promising directions of modern laboratory diagnosis of fungal infections. The main advantages of these tests are high sensitivity and specificity, as well as the ability to use any substrates containing DNA for analysis \[[@B12-jof-05-00112]\].

Early diagnosis and timely initiation of mucormycosis treatment can improve the survival of patients and give a permit to continue the treatment of underlying hematologic disease. This will also reduce the time of hospitalization and, consequently, lower the treatment cost \[[@B11-jof-05-00112]\]. However, there are not enough publications on the effectiveness of molecular methods in the diagnosis of mucormycosis in hematological patients.

The aim of this study was to analyze the results of the application of molecular methods for the diagnosis of mucormycosis in hematological patients.

2. Materials and Methods {#sec2-jof-05-00112}
========================

In a systematic search in the PubMed, Google Scholar databases we found 38 articles on molecular methods for the detection and identification of mucormycetes in various substrates. For the review we selected sources that met the following requirements: original articles in English, where oncohematological patients with diagnosed mucormycosis were included in the studies in accordance with the criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG, 15, June, 2008) \[[@B13-jof-05-00112]\].

The analysis did not include review articles, abstracts for conferences, descriptions of clinical cases, as well as articles where there were no characteristics of the background states of patients with mucormycosis, or the research results combined for various cohorts of patients, including non-hematological patients. The final search was carried out in August 2019.

3. Results and Discussion {#sec3-jof-05-00112}
=========================

The review included seven studies carried out in 2001--2017 \[[@B14-jof-05-00112],[@B15-jof-05-00112],[@B16-jof-05-00112],[@B17-jof-05-00112],[@B18-jof-05-00112],[@B19-jof-05-00112],[@B20-jof-05-00112]\] devoted to assessing the effectiveness of molecular methods for the diagnosis of mucormycosis in hematological patients. We analyzed the data from a survey of 116 oncohematological patients with mucormycosis presented in these articles ([Table 1](#jof-05-00112-t001){ref-type="table"}). The number of hematological patients in these studies was small and varied from five to 34 people. Among the examined patients, adults predominated (*n* = 110; 95%), there were significantly fewer children (*n* = 6; 5%). Meanwhile, in our register, children and adolescents accounted for 36% of all patients with mucormycosis \[[@B9-jof-05-00112]\]. Analysis of information on the treatment of background hematologic disease showed that approximately the same number of patients after cytostatic therapy and allo-HSCT were included in the studies, which coincides with the data from our register \[[@B9-jof-05-00112]\]. However, most studies were retrospective. Only in the Springer et al. 2016 study serum samples were collected and evaluated prospectively from 2008 to 2012 \[[@B16-jof-05-00112]\]. Therefore, additional prospective studies of the effectiveness of molecular methods for the diagnosis of mucormycosis in hematological patients, including children, are probably needed.

In all the works selected for this review, molecular diagnosis of mucormycosis was carried out using the polymerase chain reaction (PCR) method. Four studies used real-time PCR (RT PCR) for 18S rDNA \[[@B14-jof-05-00112],[@B15-jof-05-00112],[@B16-jof-05-00112],[@B17-jof-05-00112]\]; in two studies, the 18S rDNA region was amplified using endpoint detection \[[@B18-jof-05-00112],[@B19-jof-05-00112]\]. One study was based entirely on the determination of the sequence of internal transcribed spacer region (ITS) \[[@B20-jof-05-00112]\]. In a number of studies, DNA sequencing of either ITS or 18S rDNA regions was used to identify mucormycetes ([Table 1](#jof-05-00112-t001){ref-type="table"}).

In most cases (84%), molecular methods were used in patients with "proven" mucormycosis, according to the criteria of EORTC/MSG, 2008. The samples of patients with "possible" mycosis were less commonly used. In the study conducted by Springer et al. 2016 were included two oncohematological patients with unidentified mycosis, in whom mucormycetes were subsequently detected by RT-PCR. In addition, ten patients had a combination of mucormycosis with "probable" or "proven" aspergillosis, five patients were diagnosed with "probable" aspergillosis prior to molecular diagnosis of mucormycosis, and one patient was "proven" based on histological examination of *Fusarium* infection ([Table 2](#jof-05-00112-t002){ref-type="table"}). A combination of different types of mycoses is often detected in hematological patients. For example, according to our data, for 52% of patients mucormycosis was diagnosed 1--225 days after IA development \[[@B9-jof-05-00112]\].

Patients with localized forms of mucormycosis prevailed (*n* = 84, 72%), and lung involvement was diagnosed in 58% of these cases (*n* = 49; [Table 2](#jof-05-00112-t002){ref-type="table"}). Lesions of two or more organs were diagnosed in 26% (*n* = 30), rhinocerebral mucormycosis was in 9% of patients (*n* = 11) and isolated central nervous system damage was observed in one patient. This indicates the representativeness of the examined patients: lungs are the main localization of mucormycosis in hematological patients, rhinocerebral form and disseminated process are common \[[@B6-jof-05-00112],[@B21-jof-05-00112]\]. According to a recent review, in allo-HSCT recipients CNS mucormycosis was diagnosed in 11% of all cases, in patients with malignancies---in 4--19% \[[@B22-jof-05-00112]\].

Analysis of the etiology of mucormycosis based on the results of substrate culture were possible only in 35 out of 82 cases (43%; [Table 3](#jof-05-00112-t003){ref-type="table"}). According to this, the number of hematological patients with mucormycosis of various etiologies was small: *Rhizopus* spp. = 11, *Lichtheimia* spp. = 10, *Rhizomucor* spp. = 6, *Mucor* spp. = 4 and *Cunninghamella* spp. = 3. The combination of two mucormycetes was detected in two patients.

Etiology of mucormycosis seemed to vary in different countries. For example, *Rhizopus* spp. (34%), *Mucor* spp. (19%) and *Lichtheimia* spp. (19%) were most commonly identified in patients with mucormycosis in Europe \[[@B8-jof-05-00112]\]. In comparison with these results the main pathogens of mucormycosis in Russia were *Rhizopus* spp. (47%), *Rhizomucor* spp. (28%) and *Lichtheimia corymbifera* (17%). According to our data, cultures from bronchoalveolar lavage (BAL) fluid and other samples were positive in 65% hematological patients with mucormycosis \[[@B9-jof-05-00112]\]. Probably, additional researches of effectiveness of molecular diagnostics for various etiology of mucormycosis including *Rhizomucor* spp., *Mucor* spp., *Cunninghamella* spp. and rare pathogens are needed.

Various materials were used for molecular verification of the causative agent of mucormycosis: most often blood serum, less often postoperative and autopsy material, biopsy specimens, histological paraffin blocks, BAL fluid, pleural fluid and sputum ([Table 4](#jof-05-00112-t004){ref-type="table"}). In the study performed by Scherer et al. 2018, several substrates (BAL, serum and histological samples) were examined at once.

The obtained data indicate that molecular methods for a blood serum study can be an important tool for the diagnosis of mucormycosis in hematological patients. Millon et al. in their study showed that mucormycetes DNA can be detected in at least 36/44 (81%) patients with "probable" or "proven" mucormycosis. Due to the retrospective design of the study, serum sampling and volume were not optimal, and the sensitivity level was 81%. However, with the exception of cases with insufficient serum volume for testing, the sensitivity of the molecular method reached 92% \[[@B15-jof-05-00112]\].

Springer et al. 2016 showed a high percentage of positive results when have being used RT-PCR for 18S rDNA to analyze sera from patients with "proven" and "probable" mucormycosis. Further sequencing revealed the DNA of two different pathogens of mucormycosis (*Lichtheimia* and *Rhizopu*s) and confirmed the pathogen identified by cultural methods in four out of five cases. *Rhizopus* spp. was also identified by this method in the case when the genus was not defined in the culture \[[@B16-jof-05-00112]\].

Bronchial lavage samples were examined in 25 patients, sputum and pleural fluid in three ([Table 4](#jof-05-00112-t004){ref-type="table"}). Scherer et al. 2018 showed that the sensitivity of molecular diagnostic tests for serum and BAL samples were comparable \[[@B17-jof-05-00112]\]. It was difficult to assess the effectiveness of molecular methods in sputum and pleural fluid for the diagnosis of mucormycosis due to the small number of patients included \[[@B20-jof-05-00112]\].

Since the main localization of mucormycosis in hematological patients are lungs, additional studies of the effectiveness of molecular diagnostic methods using BAL are probably needed.

We have not found the results of the cerebrospinal fluid (CSF) study, although rhinocerebral mucormycosis was in 9.5% of the examined patients. Probably, additional studies of the effectiveness of molecular diagnostic methods using CSF are also needed.

The results of Hammond et al. 2011's studies showed that the detection of mucormycetes DNA by PCR in histological preparations (tissue fixed in paraffin was used in this work) could also be a useful tool for the diagnosis of mucormycosis. Of 27 tissue samples with initial histological signs of mucormycosis, PCR was positive in 22 samples. In addition, the researchers found a high level of correlation between the results of PCR diagnostics and culture: of 12 samples with a positive culture, mucormycosis was confirmed by PCR in 10 cases (83%), and results of sequencing corresponded to the result of culture identification to genus in nine samples. In addition, PCR diagnostics revealed molds in substrates of 12 patients in whom a fungal culture was not obtained \[[@B18-jof-05-00112]\].

Analysis of the summarized data as a result of our review indicates a high sensitivity of the molecular diagnostics of mucormycosis in a cohort of hematological patients. So, a positive PCR result was obtained in 98 cases of the 111 examined samples, thus the sensitivity was 88.2% ([Table 5](#jof-05-00112-t005){ref-type="table"}), while the culture sensitivity was 42.7% ([Table 3](#jof-05-00112-t003){ref-type="table"}).

As our literature analysis has shown, the spectrum of the methods of molecular diagnostics of mucormycosis used to date was mainly limited to RT-PCR and sequencing of 18S rDNA, as well as sequencing of the ITS region. DNA sequencing allowed us to get a slightly better taxonomic resolution, and RT-PCR met the criteria for a quick diagnostic method. In general, molecular diagnostic methods used in the studies we reviewed and intended for amplification of 18S rDNA allowed us to reach a sensitivity of 85--100%. The use of PCR identification of mucormycetes DNA in serum or BAL, along with standard mycological methods, can increase the effectiveness of early diagnosis of mucormycosis in hematological patients. At the moment an important problem is the lack of standardization of molecular methods. Fungal PCR Initiative (FPCRI)/Mucorales Lab working group of the International Society for Human and animal Mycology (ISHAM) are currently solving the questions about improving standardization and providing recommendations for Mucorales PCR assay, as was previously done for *Aspergillus* PCR assays by the European *Aspergillus* PCR Initiative (EAPCRI) working group \[[@B23-jof-05-00112],[@B24-jof-05-00112]\].

4. Conclusions {#sec4-jof-05-00112}
==============

1\. Applying molecular methods along with standard mycological methods will improve the diagnosis of mucormycosis in hematologic patients.

2\. Prospective studies of the effectiveness of molecular methods for the diagnosis of mucormycosis in hematological patients, including children, are needed.

3\. Further researches on the effectiveness of the molecular diagnosis of mucormycosis of various etiologies, including *Rhizomucor* spp., *Mucor* spp., *Cunninghamella* spp. and rare pathogens are needed.

4\. Since the main localizations of mucormycosis in hematological patients are lungs and the central nervous system, additional studies of the effectiveness of molecular diagnostic methods using BAL and CSF are needed.
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jof-05-00112-t001_Table 1

###### 

Study design.

  Author                                          Study Period             Number of Hemato-Logical Patients   Adults/Children   Chemotherapy/Allo-HSCT   Study Prospective/Retrospective   Molecular Diagnostic Method   Target
  ----------------------------------------------- ------------------------ ----------------------------------- ----------------- ------------------------ --------------------------------- ----------------------------- ------------
  Millon 2013 \[[@B14-jof-05-00112]\]             2004--2012               7                                   6/1               6/1                      retrospective                     real-time PCR                 18S rDNA
  Millon 2016 \[[@B15-jof-05-00112]\]             2012--2014               34                                  32/2              21/13                    retrospective                     real-time PCR                 18S rDNA
  sequencing                                      18S rDNA ITS                                                                                                                                                            
  Springer 2016 \[[@B16-jof-05-00112]\]           2010--2014               12                                  12/0              ND/ND                    prospective                       real-time PCR                 18S rDNA
  sequencing                                                                                                                                                                                                              
  Scherer 2018 \[[@B17-jof-05-00112]\]            2013--2017               20                                  20/0              12/8                     retrospective                     real-time PCR                 18S rDNA
  Hammond 2011 \[[@B18-jof-05-00112]\]            2001--2009               29                                  29/0              14/15                    retrospective                     PCR                           18S rDNA
  sequencing                                                                                                                                                                                                              
  Gholinejad-Ghadi 2018 \[[@B19-jof-05-00112]\]   2004--2007; 2015--2017   5                                   3/2               ND/ND                    retrospective                     PCR                           18S rDNA
  sequencing                                      18S rDNA region ITS                                                                                                                                                     
  Guinea 2017 \[[@B20-jof-05-00112]\]             2007--2015               9                                   8/1               6/3                      retrospective                     PCR                           region ITS
  sequencing                                                                                                                                                                                                              
  Total:                                                                   116                                 110/6             59/40                                                                                    

ND: no data.

jof-05-00112-t002_Table 2

###### 

Characteristics of mucormycosis in hematological patients.

  Author                  Number of Hemato-Logical Patients   Proven/Probable Mucormycosis   Possible/Unidentified Mycosis   Including: Mixed Infection (Mucor-Mycosis + Invasive Aspergillosis)   Other Mycoses   Isolated Mucor-Mycosis: Lung/Others   2 and \> Organs/Rhino-Cerebral
  ----------------------- ----------------------------------- ------------------------------ ------------------------------- --------------------------------------------------------------------- --------------- ------------------------------------- --------------------------------
  Millon 2013             7                                   7/-                            \-                              1                                                                     \-              1/-                                   4/2
  Millon 2016             34                                  18/16                          \-                              6                                                                     ND              16/2                                  11/5
  Springer 2016           12                                  5 ^a^                          5/2                             \-                                                                    \-              1/3 ^e^                               1/-
  Scherer 2018            20                                  5/3                            7                               2                                                                     4 ^b/^1 ^c^     19/1 ^d^                              \-
  Hammond 2011            29                                  29/-                           \-                              \-                                                                    \-              6/11                                  12/-
  Gholinejad-Ghadi 2018   5                                   5/-                            \-                              \-                                                                    \-              \-                                    1/4
  Guinea 2017             9                                   4/5                            \-                              1 ^b^                                                                 \-              6/2                                   1/-
  Total:                  116                                 97                             14                              10                                                                    5               49/19                                 30/11

^a^ cases of "proven" or "probable" mucormycosis. ^b^ "probable" invasive aspergillosis; ^c^ "proven" fusariosis; ^d^ central nervous system (CNS); ^e^ no localization data in seven patients. ND: no data.

jof-05-00112-t003_Table 3

###### 

Etiology of mucormycosis in hematological patients.

  Author                  Number of Hemato-Logical Patients   Positive Culture (Number)   *Rhizopus* spp.   *Mucor* spp.   *Cunninghamella* spp.   *Rhizomucor* spp.   *Lichtheimia* spp.   2 or More Mucormycetes
  ----------------------- ----------------------------------- --------------------------- ----------------- -------------- ----------------------- ------------------- -------------------- ------------------------
  Millon 2013             7                                   5                           2                 0              0                       0                   3                    
  Millon 2016             NA ^b^                              NA                          NA                NA             NA                      NA                  NA                   NA
  Springer 2016           12                                  5                           2                 1              0                       0                   2                    0
  Scherer 2018            20                                  3                           0                 0              0                       2                   1                    
  Hammond 2011            29                                  13                          5                 3              2                       2                   1                    1
  Gholinejad-Ghadi 2018   5                                   1 ^a^                       1                 0              0                       0                   0                    
  Guinea 2017             9                                   8 ^c^                       1                 0              1                       2                   3                    \-
  Total:                  82                                  35                          11                4              3                       6                   10                   1

^a^ no data for other patients; ^b^ analysis of the etiology of mucormycosis based only on the cultural method was not possible. ^c^ one of eight isolates was not available for study.

jof-05-00112-t004_Table 4

###### 

Samples used for molecular diagnostics.

  Author                  Number of Hematological Patients   Samples                                                            Histology, Biopsy Specimens   BAL   Sputum, Pleural Fluid   Serum
  ----------------------- ---------------------------------- ------------------------------------------------------------------ ----------------------------- ----- ----------------------- --------
  Millon 2013             7                                  tissue (fresh or paraffin-embedded)                                7                             \-    \-                      \-
  Millon 2016             34 ^a^                             serum                                                              \-                            \-    \-                      34 ^a^
  Springer 2016           12 ^b^                             serum                                                              \-                            \-    \-                      12
  Scherer 2018            20                                 histology; BAL, serum                                              6                             20    \-                      19
  Hammond 2011            29                                 histology, tissue aspirates, autopsy specimens, biopsy specimens   29 ^c^                        \-    \-                      \-
  Gholinejad-Ghadi 2018   5                                  formalin-fixed paraffin-embedded samples                           5                             \-    \-                      \-
  Guinea 2017             9                                  BAL/bronchial secretions, pleural fluid, sputum, biopsy tissue     4                             5     3                       \-
  Total:                  116                                                                                                   51                            25    3                       65

^a^ 1 and \> serum samples were obtained from each of 34 patients. ^b^ the study included only hematological patients in whom species identification was performed using molecular diagnostic methods. ^c^ including five autopsy samples.

jof-05-00112-t005_Table 5

###### 

Cultures and PCR results.

  Author                  Number of Hematological Patients   PCR Was Performed   PCR (+) Total   PCR (+)/Cultures (+)   PCR (--)/Cultures (+)   PCR (+)/Cultures (--) or Unavailable   PCR (--)/Cultures (--) or Unavailable
  ----------------------- ---------------------------------- ------------------- --------------- ---------------------- ----------------------- -------------------------------------- ---------------------------------------
  Millon 2013             7                                  7                   7               5/5                    0                       2/2                                    \-
  Millon 2016             34                                 34                  30              NA                     NA                      NA                                     \-
  Springer 2016           12                                 12                  12              5/5                    0                       7/7                                    \-
  Scherer 2018            20                                 20                  20 ^a^          3/3                    0                       17/17                                  \-
  Hammond 2011            29                                 27                  22              10/12                  2/12                    12/15                                  3/15
  Gholinejad-Ghadi 2018   5                                  5                   4               1/1                    0                       3/4                                    1/1
  Guinea 2017             9                                  6                   3               2/5                    3/5                     1/1                                    \-
  Total:                  116                                111                 98              26/31                  5/17                    42/46                                  

^a^ PCR assay was positive in bronchoalveolar lavage (BAL) and/or serum in all patients. NA: not applicable.
